187 related articles for article (PubMed ID: 31270151)
21. NT21MP negatively regulates paclitaxel-resistant cells by targeting miR‑155‑3p and miR‑155-5p via the CXCR4 pathway in breast cancer.
Wang Y; Yan L; Zhang L; Xu H; Chen T; Li Y; Wang H; Chen S; Wang W; Chen C; Yang Q
Int J Oncol; 2018 Sep; 53(3):1043-1054. PubMed ID: 30015868
[TBL] [Abstract][Full Text] [Related]
22. Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice.
Aggarwal BB; Shishodia S; Takada Y; Banerjee S; Newman RA; Bueso-Ramos CE; Price JE
Clin Cancer Res; 2005 Oct; 11(20):7490-8. PubMed ID: 16243823
[TBL] [Abstract][Full Text] [Related]
23. Aryl hydrocarbon receptor/cytochrome P450 1A1 pathway mediates breast cancer stem cells expansion through PTEN inhibition and β-Catenin and Akt activation.
Al-Dhfyan A; Alhoshani A; Korashy HM
Mol Cancer; 2017 Jan; 16(1):14. PubMed ID: 28103884
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of Integrin-HER2 signaling by Cucurbitacin B leads to in vitro and in vivo breast tumor growth suppression.
Gupta P; Srivastava SK
Oncotarget; 2014 Apr; 5(7):1812-28. PubMed ID: 24729020
[TBL] [Abstract][Full Text] [Related]
25. Docosahexaenoic acid inhibited the Wnt/β-catenin pathway and suppressed breast cancer cells in vitro and in vivo.
Xue M; Wang Q; Zhao J; Dong L; Ge Y; Hou L; Liu Y; Zheng Z
J Nutr Biochem; 2014 Feb; 25(2):104-10. PubMed ID: 24290517
[TBL] [Abstract][Full Text] [Related]
26. Disulfide bond disrupting agents activate the unfolded protein response in EGFR- and HER2-positive breast tumor cells.
Ferreira RB; Wang M; Law ME; Davis BJ; Bartley AN; Higgins PJ; Kilberg MS; Santostefano KE; Terada N; Heldermon CD; Castellano RK; Law BK
Oncotarget; 2017 Apr; 8(17):28971-28989. PubMed ID: 28423644
[TBL] [Abstract][Full Text] [Related]
27. Inotodiol suppresses proliferation of breast cancer in rat model of type 2 diabetes mellitus via downregulation of β-catenin signaling.
Zhang X; Bao C; Zhang J
Biomed Pharmacother; 2018 Mar; 99():142-150. PubMed ID: 29331760
[TBL] [Abstract][Full Text] [Related]
28. Adiponectin modulates the glycogen synthase kinase-3beta/beta-catenin signaling pathway and attenuates mammary tumorigenesis of MDA-MB-231 cells in nude mice.
Wang Y; Lam JB; Lam KS; Liu J; Lam MC; Hoo RL; Wu D; Cooper GJ; Xu A
Cancer Res; 2006 Dec; 66(23):11462-70. PubMed ID: 17145894
[TBL] [Abstract][Full Text] [Related]
29. Inhibiting the MNK-eIF4E-β-catenin axis increases the responsiveness of aggressive breast cancer cells to chemotherapy.
Li Z; Sun Y; Qu M; Wan H; Cai F; Zhang P
Oncotarget; 2017 Jan; 8(2):2906-2915. PubMed ID: 27926520
[TBL] [Abstract][Full Text] [Related]
30. Caspase-dependent and caspase-independent induction of apoptosis in breast cancer by fucoidan via the PI3K/AKT/GSK3β pathway in vivo and in vitro.
Xue M; Ji X; Xue C; Liang H; Ge Y; He X; Zhang L; Bian K; Zhang L
Biomed Pharmacother; 2017 Oct; 94():898-908. PubMed ID: 28810530
[TBL] [Abstract][Full Text] [Related]
31. Targeting of Wnt/β-Catenin by Anthelmintic Drug Pyrvinium Enhances Sensitivity of Ovarian Cancer Cells to Chemotherapy.
Zhang C; Zhang Z; Zhang S; Wang W; Hu P
Med Sci Monit; 2017 Jan; 23():266-275. PubMed ID: 28090074
[TBL] [Abstract][Full Text] [Related]
32. BI2536--A PLK inhibitor augments paclitaxel efficacy in suppressing tamoxifen induced senescence and resistance in breast cancer cells.
Prashanth Kumar BN; Rajput S; Bharti R; Parida S; Mandal M
Biomed Pharmacother; 2015 Aug; 74():124-32. PubMed ID: 26349973
[TBL] [Abstract][Full Text] [Related]
33. Positive interaction between lapatinib and capecitabine in human breast cancer models: study of molecular determinants.
Chefrour M; Milano G; Formento P; Giacometti S; Denden A; Renée N; Iliadis A; Fischel JL; Ciccolini J
Fundam Clin Pharmacol; 2012 Aug; 26(4):530-7. PubMed ID: 21623901
[TBL] [Abstract][Full Text] [Related]
34. LW-213 induces G2/M cell cycle arrest through AKT/GSK3β/β-catenin signaling pathway in human breast cancer cells.
Zhao L; Miao HC; Li WJ; Sun Y; Huang SL; Li ZY; Guo QL
Mol Carcinog; 2016 May; 55(5):778-92. PubMed ID: 25945460
[TBL] [Abstract][Full Text] [Related]
35. Obesity Suppresses Estrogen Receptor Beta Expression in Breast Cancer Cells via a HER2-Mediated Pathway.
Bowers LW; Wiese M; Brenner AJ; Rossi EL; Tekmal RR; Hursting SD; deGraffenried LA
PLoS One; 2015; 10(12):e0145452. PubMed ID: 26709918
[TBL] [Abstract][Full Text] [Related]
36. Silencing dishevelled-1 sensitizes paclitaxel-resistant human ovarian cancer cells via AKT/GSK-3β/β-catenin signalling.
Zhang K; Song H; Yang P; Dai X; Li Y; Wang L; Du J; Pan K; Zhang T
Cell Prolif; 2015 Apr; 48(2):249-58. PubMed ID: 25643607
[TBL] [Abstract][Full Text] [Related]
37. Myricetin suppresses p21-activated kinase 1 in human breast cancer MCF-7 cells through downstream signaling of the β-catenin pathway.
Jiao D; Zhang XD
Oncol Rep; 2016 Jul; 36(1):342-8. PubMed ID: 27122002
[TBL] [Abstract][Full Text] [Related]
38. Effects of Jiazhu decoction in combination with cyclophosphamide on breast cancer in mice.
Guan H; Xie S; Liu S; Xie Q; Hou S; Liu H; Zhang Y; Hu Y; Zhang C
J Tradit Chin Med; 2019 Oct; 39(5):642-648. PubMed ID: 32186113
[TBL] [Abstract][Full Text] [Related]
39. Trastuzumab-resistant HER2-driven breast cancer cells are sensitive to epigallocatechin-3 gallate.
Eddy SF; Kane SE; Sonenshein GE
Cancer Res; 2007 Oct; 67(19):9018-23. PubMed ID: 17909003
[TBL] [Abstract][Full Text] [Related]
40. Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib.
Huang W; Wu QD; Zhang M; Kong YL; Cao PR; Zheng W; Xu JH; Ye M
Cancer Lett; 2015 Jan; 356(2 Pt B):862-71. PubMed ID: 25449780
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
